The choice of a monotherapy with JAK inhibitors, ABA, or IL-6 inhibitors was mainly due to MTX withdrawal for inefficacy or side effects in 34.3% of patients defined as D2T-RA [21]. Here, IL6 is linked to rheumatoid arthritis.